Literature DB >> 3959581

Cancer of the kidney invading the vena cava and heart. Results after 11 years of treatment.

C D Vaislic, P Puel, P Grondin, A Vargas, A Thevenet, F Fontan, C Deville, A Leguerrier, B Touchot, A Piwnica.   

Abstract

Between October, 1973, and October, 1983, 18 patients with cancer of the kidney or adrenal gland that had invaded the vena cava, and in 11 cases had reached the heart, were operated on by seven surgical teams. The surgical excision in all patients was performed with extracorporeal circulation, circulatory arrest and deep hypothermia. No deaths occurred. If there are no detectable metastases before operation, the 5 year survival rate is 75% as compared to 6 months with medical treatment. This clinical situation is not uncommon, as 3% to 10% of cancers of the kidney invade the inferior vena cava and 40% of them reach the heart. The possibility of curing the cancers with minimal operative risk should prompt a systematic search for venous invasion with any cancer of the kidney.

Entities:  

Mesh:

Year:  1986        PMID: 3959581

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Locally advanced renal cell carcinoma.

Authors:  Mohammed Al Otaibi; Simon Tanguay
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

Review 2.  Caval thrombus in conjunction with renal tumors: indication for surgery and technical details.

Authors:  J González; G Ciancio
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

3.  Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival.

Authors:  D G Skinner; T R Pritchett; G Lieskovsky; S D Boyd; Q R Stiles
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

4.  Liver transplantation techniques with preservation of the natural venovenous bypass: effect on surgical resection of renal cell carcinoma invading the inferior vena cava.

Authors:  Spiros Delis; Christos Dervenis; Dimitrios Lytras; Costas Avgerinos; Mark Soloway; Gaetano Ciancio
Journal:  World J Surg       Date:  2004-06       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.